Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema
Phase of Trial: Phase III
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms DRCR AC
- 15 Dec 2017 Planned End Date changed from 20 Nov 2019 to 6 Dec 2019.
- 15 Dec 2017 Planned primary completion date changed from 20 Nov 2019 to 6 Dec 2019.
- 15 Dec 2017 Status changed from not yet recruiting to recruiting.